The joint venture will produce vaccines for children at a new facility to be built by GSK, which will invest $32m for a 65% stake in the joint venture. Jiangsu Walvax Biotech will invest $22m and hold the remaining stake. GSK is expected to provide an additional $11.6m in 2015.